Key Points
- Major shareholder Private Ltd Gic sold 590,284 Medline shares for approximately $21.0 million at an average price of $35.58, reducing its stake by 2.36% to 24.4 million shares. The investor also reported additional sales of more than 2.2 million shares earlier in the week.
- Medline reported quarterly EPS of $0.50, exceeding analyst estimates of $0.32, on $7.68 billion in revenue. Shares opened at $35.04, well below their 52-week high of $50.88.
- Analyst sentiment remains broadly positive, with a consensus “Moderate Buy” rating and a $47.69 price target, though Wells Fargo downgraded the stock to Equal Weight with a $34 target. A law firm’s investigation into potential securities-law violations adds legal and reputational risk.
Medline (NASDAQ:MDLN - Get Free Report) major shareholder Private Ltd Gic sold 590,284 shares of Medline stock in a transaction dated Friday, August 7th. The shares were sold at an average price of $35.58, for a total transaction of $21,002,304.72. Following the completion of the sale, the insider directly owned 24,402,482 shares in the company, valued at approximately $868,240,309.56. The trade was a 2.36% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Large shareholders that own at least 10% of a company's stock are required to disclose their transactions with the SEC.
Private Ltd Gic also recently made the following trade(s):
- On Thursday, August 6th, Private Ltd Gic sold 271,994 shares of Medline stock. The stock was sold at an average price of $35.33, for a total transaction of $9,609,548.02.
- On Wednesday, August 5th, Private Ltd Gic sold 1,976,618 shares of Medline stock. The shares were sold at an average price of $35.60, for a total transaction of $70,367,600.80.
Medline Price Performance
Shares of MDLN opened at $35.04 on Wednesday. The company has a current ratio of 4.33, a quick ratio of 2.61 and a debt-to-equity ratio of 0.66. The stock's 50 day moving average is $38.21 and its two-hundred day moving average is $41.57. Medline has a twelve month low of $32.81 and a twelve month high of $50.88. The firm has a market capitalization of $46.03 billion and a PE ratio of 109.50.
Medline (NASDAQ:MDLN - Get Free Report) last issued its earnings results on Wednesday, August 5th. The company reported $0.50 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.32 by $0.18. The business had revenue of $7.68 billion for the quarter. Research analysts anticipate that Medline will post 1.49 earnings per share for the current year.
Key Stories Impacting Medline
Here are the key news stories impacting Medline this week:
- Positive Sentiment: TD Cowen maintained a Buy rating and set a $45 price target, implying substantial upside from recent levels. The firm cited Medline’s strong cash flow and longer-term growth outlook. TD Cowen Medline rating
- Positive Sentiment: Tigress Financial lowered its price target from $62 to $55 but retained a Buy rating. The revised target still represents significant potential upside, suggesting the analyst views recent weakness as excessive. Benzinga analyst action
- Neutral Sentiment: Reported short interest was listed at zero shares, unchanged from the prior period, with a zero-day short-interest ratio. Because the figures include an apparent “NaN” calculation, the data may be incomplete or unreliable and offers little actionable insight for investors.
- Negative Sentiment: Wells Fargo cut its price target from $45 to $34 and changed its stance to Equal Weight. The new target is slightly below the recent trading level, signaling limited near-term upside in the firm’s view. Wells Fargo Medline price target
- Negative Sentiment: Major shareholder Private Ltd Gic sold approximately 590,284 shares worth $21.0 million, reducing its ownership by 2.36%. While the investor still holds a substantial stake, the sale may add modest pressure or raise concerns about insider sentiment. SEC ownership filing
- Negative Sentiment: Law firm Kaplan Fox announced an investigation into potential securities-law violations involving Medline. The announcement does not establish wrongdoing, but it introduces legal and reputational risk and may weigh on investor confidence. Kaplan Fox Medline investigation
Institutional Trading of Medline
Large investors have recently bought and sold shares of the company. Bank of New York Mellon Corp purchased a new position in shares of Medline in the second quarter valued at $40,430,000. E. Ohman J or Asset Management AB acquired a new position in shares of Medline during the 2nd quarter worth $508,000. GAMMA Investing LLC boosted its position in shares of Medline by 68.3% in the 2nd quarter. GAMMA Investing LLC now owns 626 shares of the company's stock worth $25,000 after buying an additional 254 shares in the last quarter. Parallel Advisors LLC boosted its position in shares of Medline by 1,073.3% in the 1st quarter. Parallel Advisors LLC now owns 5,280 shares of the company's stock worth $235,000 after buying an additional 4,830 shares in the last quarter. Finally, CTC Alternative Strategies Ltd. acquired a new stake in Medline in the 1st quarter valued at about $1,048,000.
Wall Street Analyst Weigh In
MDLN has been the subject of a number of recent analyst reports. Wells Fargo & Company reduced their target price on Medline from $45.00 to $34.00 and set an "equal weight" rating for the company in a report on Tuesday. Robert W. Baird set a $42.00 price target on shares of Medline in a research note on Thursday, August 6th. TD Cowen cut their price target on shares of Medline from $53.00 to $45.00 and set a "buy" rating for the company in a report on Monday. Citigroup raised shares of Medline to a "strong-buy" rating in a report on Wednesday, August 5th. Finally, Barclays lowered their target price on shares of Medline from $50.00 to $45.00 and set an "overweight" rating on the stock in a research report on Monday, June 1st. Two research analysts have rated the stock with a Strong Buy rating, twenty-one have given a Buy rating, five have given a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $47.69.
Read Our Latest Stock Report on Medline
Medline Company Profile
(
Get Free Report)
Medline (NASDAQ: MDLN) is a healthcare products and services company that manufactures, sources and distributes a wide range of medical supplies and equipment for healthcare providers. Its product portfolio spans clinical consumables and personal protective equipment, surgical and procedural supplies, wound care and incontinence products, diagnostic and laboratory supplies, and select durable medical equipment. Medline supports care settings that include hospitals, health systems, long-term care facilities, ambulatory clinics and home health providers.
In addition to product manufacturing and distribution, Medline provides supply‑chain and logistics services designed to help healthcare customers manage inventory, reduce costs and streamline operations.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
